<DOC>
	<DOC>NCT00112060</DOC>
	<brief_summary>This phase I/II, multi-centered, non-randomized trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with NSCLC.</brief_summary>
	<brief_title>A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Age â‰¥ 18 years Histologically or cytologically confirmed NSCLC which is stage III or stage IV, or recurrent disease, and failed therapy with a standard first line (Phase I/II) as well as second line chemotherapy regimen (Phase I), or be intolerant of standard chemotherapy. Receipt of one additional prior chemotherapy regimen for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant is allowable. A prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTK) antagonist is allowable (Phase II). Asymptomatic or treated brain metastases (including steroids) if last therapy was received &gt; 4 weeks from study entry and is deemed by the investigator to have a low likelihood of rapid deterioration. ECOG performance status 0 2. Adequate organ function and bone marrow reserve. Use of appropriate contraceptive method. Signed patient informed consent. Investigational agents within 30 days prior to Day 1 of study. Known symptomatic or uncontrolled brain metastases. Uncontrolled intercurrent illness. Known human immunodeficiency virus (HIV), hepatitis A, B, C, D and E. Patient has uncontrolled pleural effusions. Patient has received nitrosoureas or mitomycinC within 6 weeks or other chemotherapy or radiation therapy within 3 weeks before study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Talotrexin</keyword>
	<keyword>PT-523</keyword>
	<keyword>Non-Small Cell Lung Carcinoma (NSCLC)</keyword>
</DOC>